Powering the Future of Cell and Gene Therapy
Virocell Biologics, a leading name in vector manufacturing for cell and gene therapy trials, has joined forces with Avencell Therapeutics Inc., a clinical-stage biotech company developing next-gen allogeneic CAR-T cell therapies. Together, they aim to fast-track the development of AVC-203 a cutting-edge, multi-targeted CAR-T therapy designed to treat both autoimmune disorders and B-cell malignancies.
The partnership centers around the production of AVC-203, which targets CD19 and CD20 using a first-of-its-kind retroviral vector—a critical component in its manufacturing process. Virocell will provide the vector, leveraging its deep expertise and proven track record in high-yield production.
The Innovation Behind AVC-203
AVC-203 is Avencell’s second allogeneic CAR-T program and represents a major step toward “off-the-shelf” treatments that avoid common complications like graft-versus-host disease. The therapy is uniquely designed to minimize immune rejection by the body’s natural killer (NK) and T cells.
What truly sets AVC-203 apart is Avencell’s proprietary RevCAR receptor, which allows switchable, multi-antigen targeting a powerful tool that increases precision and safety during treatment. The goal is to match or exceed the effectiveness of current CAR-T therapies, while reducing treatment complexity, cost, and delays.
Why Virocell?
Avencell selected Virocell as its vector manufacturing partner based on the CDMO’s speed, reliability, and technical excellence. Virocell integrated Avencell’s proprietary cell line into its GMP-compliant process and delivered high-yield retroviral vectors that met Avencell’s aggressive development timeline.
Thanks to this collaboration, AVC-203 is now on track to enter phase 1 clinical trials in patients with relapsed/refractory B-cell lymphoma in the second half of 2025.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Leadership Commentary
John W. Hadden II, CEO of Virocell Biologics, stated:
“We’re thrilled to partner with Avencell and contribute to their pioneering CAR-T platform. This project showcases Virocell’s strength in delivering complex retroviral vectors and supporting life-changing therapies where they’re needed most.”
Andrew Schiermeier, PhD, CEO of Avencell, added:
“We chose Virocell because they deliver where others can’t. Their work on the AVC-203 retroviral vector exceeded expectations and reinforced our confidence in their team. This collaboration marks an exciting milestone as we prepare for clinical entry.”
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
